Trial Profile
A Pilot Study to Evaluate the Combination of VB10.NEO with NKTR-214 in Patients with Advanced or Metastatic Squamous Cell Carcinoma of Head and Neck
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; VB10-NEO (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 12 Aug 2020 Status changed from planning to recruiting, according to a Vaccibody media release.
- 12 Aug 2020 According to a Vaccibody media release, first patient has been dosed.
- 02 Apr 2019 According to a Nektar Therapeutics media release, this study is planned to begin mid-2019.